Finanzen von Madrigal Pharmaceuticals Inc (MDGL)MDGLMadrigal Pharmaceuticals Inc

Evaluating the bottom line, Madrigal Pharmaceuticals, Inc. maintains a gross margin of 89.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.46%, while the net margin is -15.91%. These profitability ratios, combined with a Return on Equity (ROE) of -53.31%, provide a clear picture of how effectively MDGL converts its operational activities into shareholder value.

In the context of the broader market, MDGL competes directly with industry leaders such as IBRX and AAPG. With a market capitalization of $10.39B, it holds a significant position in the sector. When comparing efficiency, MDGL's gross margin of 89.02% stands against IBRX's 99.42% and AAPG's 96.12%. Such benchmarking helps identify whether Madrigal Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Madrigal's gross margin remains high at 89.02% in Q2 2026, indicating strong profitability potential despite ongoing net losses. The company's total revenue has shown a consistent upward trend, reaching $364.3 million in Q2 2026, up from $287.3 million in Q3 2025.